The Health Resources and Services Administration on Feb. 25 extended the comment window for the request for information (RFI) on rebate models in the 340B Drug Pricing Program. The announcement follows a Feb. 19 request from America’s Essential Hospitals and other stakeholders to extend the comment period. The new deadline to respond to the RFI is April 20.
America’s Essential Hospitals has prepared a template comment letter for members to consider submitting to HRSA in response to this RFI.
In a separate Information Collection Request issued Feb. 25, HRSA stated the scope of the potential 340B Rebate Model Pilot Program will be “limited to manufacturers with Medicare Drug Price Negotiation Program Agreements with the Centers for Medicare & Medicaid Services’ for the initial price applicability years 2026 and 2027.” This makes the earliest likely start date of a future pilot program Jan. 1, 2027.
Across 2026 and 2027, a total of 25 drugs have been selected for negotiation—10 drugs associated with nine manufacturers for 2026 and 15 additional drugs for 2027, bringing the combined total to 13 unique manufacturers across both years.
Contact Director of Policy Rob Nelb, MPH, at rnelb@essentialhospitals.org or 202.585.0127 with questions.
Author